[go: up one dir, main page]

PL2261378T3 - Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I - Google Patents

Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I

Info

Publication number
PL2261378T3
PL2261378T3 PL10182056T PL10182056T PL2261378T3 PL 2261378 T3 PL2261378 T3 PL 2261378T3 PL 10182056 T PL10182056 T PL 10182056T PL 10182056 T PL10182056 T PL 10182056T PL 2261378 T3 PL2261378 T3 PL 2261378T3
Authority
PL
Poland
Prior art keywords
fusion
present
viruses
class
inhibiting
Prior art date
Application number
PL10182056T
Other languages
English (en)
Inventor
Robert F Garry
Russell B Wilson
Original Assignee
The Administrators Of The Tulane Educational Fund
Autoimmune Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund, Autoimmune Tech Llc filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL2261378T3 publication Critical patent/PL2261378T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PL10182056T 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I PL2261378T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51718103P 2003-11-04 2003-11-04
EP04810256A EP1692265B1 (en) 2003-11-04 2004-11-03 Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
EP10182056.1A EP2261378B1 (en) 2003-11-04 2004-11-03 Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in RNA viruses having class i membrane fusogenic envelope proteins

Publications (1)

Publication Number Publication Date
PL2261378T3 true PL2261378T3 (pl) 2014-03-31

Family

ID=34572923

Family Applications (4)

Application Number Title Priority Date Filing Date
PL10182056T PL2261378T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
PL04810256T PL1692265T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
PL10182040T PL2261376T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
PL10182049T PL2261377T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL04810256T PL1692265T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
PL10182040T PL2261376T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
PL10182049T PL2261377T3 (pl) 2003-11-04 2004-11-03 Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I

Country Status (12)

Country Link
US (5) US7491793B2 (pl)
EP (7) EP2261378B1 (pl)
JP (1) JP5008398B2 (pl)
AT (1) ATE518967T1 (pl)
AU (2) AU2004288218B2 (pl)
BR (1) BRPI0416187A (pl)
CA (1) CA2544848C (pl)
DK (7) DK2261374T3 (pl)
ES (7) ES2392891T3 (pl)
PL (4) PL2261378T3 (pl)
PT (4) PT2261377E (pl)
WO (1) WO2005044992A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2261374T3 (da) 2003-11-04 2012-09-10 Univ Tulane Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
KR20180021930A (ko) * 2007-06-25 2018-03-05 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 인플루엔자를 억제하는 조성물 및 방법
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US10138276B2 (en) * 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
WO2011094363A2 (en) 2010-01-26 2011-08-04 The Regents Of The University Of Colorado Influenza virus compositions and methods for universal vaccines
WO2011103453A2 (en) * 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
US20130289246A1 (en) * 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
CN116162175A (zh) 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
BR112015014482A2 (pt) 2012-12-18 2017-11-21 Icahn School Med Mount Sinai vacinas para vírus influenza e seus usos
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) * 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
WO2016049380A1 (en) * 2014-09-24 2016-03-31 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2022551813A (ja) * 2019-09-04 2022-12-14 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 麻疹に対する併用抗ウイルス療法
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
JP7598538B2 (ja) * 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
AU2022249423A1 (en) * 2021-03-30 2023-11-09 Baylor College Of Medicine Methods and compositions for high-potency polypeptide-based protein inhibition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) * 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
JPH11209281A (ja) * 1998-01-21 1999-08-03 Daikin Ind Ltd ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
EP1167382A1 (en) * 1999-03-31 2002-01-02 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU7089600A (en) * 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
JP2003522948A (ja) * 2000-02-10 2003-07-29 パナコス ファーマシューティカルズ， インコーポレイテッド ウイルス融合インヒビターの検出のための分析
GB0022969D0 (en) 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
CA2423004C (en) * 2000-09-22 2012-09-11 Whitehead Institute For Biomedical Research Peptide inhibitors of hiv entry
WO2002079239A2 (en) * 2001-01-31 2002-10-10 U.S. Army Medical Research Institute Of Infectious Diseases Chimeric filovirus glycoprotein
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
KR100906102B1 (ko) * 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
JP4651213B2 (ja) * 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2005016238A2 (en) 2003-05-08 2005-02-24 Duke University Severe acute respiratory syndrome
WO2004111081A2 (en) * 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
TW200510450A (en) * 2003-07-21 2005-03-16 Nat Inst Health Soluble fragments of the SARS-CoV spike glycoprotein
DK2261374T3 (da) 2003-11-04 2012-09-10 Univ Tulane Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner

Also Published As

Publication number Publication date
ES2425600T3 (es) 2013-10-16
DK2261380T3 (da) 2013-10-07
EP2261375A3 (en) 2011-06-22
ATE518967T1 (de) 2011-08-15
HK1152084A1 (en) 2012-02-17
US9056900B2 (en) 2015-06-16
ES2437858T3 (es) 2014-01-14
HK1152083A1 (en) 2012-02-17
CA2544848A1 (en) 2005-05-19
EP2261376A2 (en) 2010-12-15
PT2261376E (pt) 2013-09-23
EP1692265B1 (en) 2011-08-03
US20060280754A1 (en) 2006-12-14
US20150239940A1 (en) 2015-08-27
EP2261377B1 (en) 2013-10-02
US20140045743A1 (en) 2014-02-13
ES2372633T3 (es) 2012-01-25
CA2544848C (en) 2015-12-29
AU2010201046B2 (en) 2013-06-27
AU2004288218B2 (en) 2009-12-24
EP2261378A3 (en) 2011-06-15
EP2261378A2 (en) 2010-12-15
EP2261380A2 (en) 2010-12-15
US8598116B2 (en) 2013-12-03
EP1692265A4 (en) 2007-08-29
US7491793B2 (en) 2009-02-17
EP1692265A2 (en) 2006-08-23
EP2261374A3 (en) 2011-03-02
PT2261378E (pt) 2013-12-09
PL1692265T3 (pl) 2011-12-30
EP2261375B1 (en) 2013-01-23
ES2427847T3 (es) 2013-11-04
PL2261377T3 (pl) 2014-03-31
JP5008398B2 (ja) 2012-08-22
EP2261378B1 (en) 2013-10-09
PL2261376T3 (pl) 2014-04-30
US20090264362A1 (en) 2009-10-22
DK2261378T3 (da) 2014-01-20
JP2007514408A (ja) 2007-06-07
PT2261377E (pt) 2013-11-29
EP2261375A2 (en) 2010-12-15
EP2261377A2 (en) 2010-12-15
WO2005044992A2 (en) 2005-05-19
HK1152085A1 (en) 2012-02-17
US20120289458A1 (en) 2012-11-15
ES2435941T3 (es) 2013-12-26
WO2005044992A3 (en) 2006-12-07
EP2261380B1 (en) 2013-07-17
BRPI0416187A (pt) 2007-01-23
EP2261380A3 (en) 2011-02-23
ES2392891T3 (es) 2012-12-14
DK2261376T3 (da) 2013-10-07
EP2261377A3 (en) 2011-05-18
HK1152086A1 (en) 2012-02-17
EP2261374A2 (en) 2010-12-15
ES2400456T3 (es) 2013-04-10
EP2261376B1 (en) 2013-07-10
HK1152082A1 (en) 2012-02-17
AU2004288218A1 (en) 2005-05-19
HK1152081A1 (en) 2012-02-17
EP2261374B1 (en) 2012-06-06
US9725487B2 (en) 2017-08-08
DK1692265T3 (da) 2011-11-21
DK2261374T3 (da) 2012-09-10
AU2010201046A1 (en) 2010-04-08
PT1692265E (pt) 2011-10-11
EP2261376A3 (en) 2011-02-23
DK2261377T3 (da) 2014-01-06
DK2261375T3 (da) 2013-04-22

Similar Documents

Publication Publication Date Title
PL2261378T3 (pl) Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
NZ598000A (en) Composition for treating hbv infection
Albarino et al. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
EP1507791A4 (en) ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
WO2005007805A3 (en) ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
J Blake et al. RNA interference for viral infections
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
WO2004044220A3 (en) Flaviviris fusion inhibitors
EA200601218A1 (ru) Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
WO2024229446A2 (en) Rna vectors with hairpin-like inserts
WO2002000924A3 (en) Viral phospholipase a2 enzymes, anti-viral agents and methods of use
WO2002074941A8 (de) Reportervirus mit heterologen hüllproteinen
Ellenberg et al. Synthesis and expression of viral antigens in Vero cells persistently infected with Junin virus
Uhl Cellular Conflicts Between RNA Virus and Host Biology
Mokhtari Copyright© 2019 A. MOKHTARI, M. MAHZOUNIEH, O. MADADGAR, A. GHALYANCHI LANGEROUDI
WO2022065983A3 (ko) 돌외 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물
Madsen Dependence of Two Arboviruses on the Host MicroRNA Pathway
Shah The Development of Resistance of Human Immunodeficiency Virus to RNA Interference Therapies: Understanding Mechanism and Developing Strategies to Overcome
TW200738626A (en) Methods for treating hepatitis C
TW200519210A (en) Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same